GlassScriptPhysician profile
Noel E Delgadillo
NPI 1467548594
$4,334.91
in general payments reported to CMS, 2019-2025
14 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.93 · 2020: $226 · 2021: $362 · 2022: $525 · 2023: $429 · 2024: $2,323 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,604 · Consulting Fee: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.91 |
| Consulting Fee | $1,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $1,969.93 | 2024-2025 | Auvelity |
| Lundbeck LLC | $876.89 | 2020-2025 | Rexulti |
| Abbvie INC. | $526.42 | 2021-2023 | Vraylar |
| Bausch Health US, LLC | $387.63 | 2022-2025 | Aplenzin |
| Allergan, INC. | $169.24 | 2020 | |
| Tris Pharma INC | $99.93 | 2023-2025 | Dyanavel Xr |
| Corium, LLC | $87.73 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $79.69 | 2020-2024 | Trintellix |
| Neos Therapeutics, LP | $41.33 | 2024 | Adzenys Xr-Odt |
| Otsuka America Pharmaceutical, INC. | $24.34 | 2020 | |
| Almatica Pharma LLC | $21.99 | 2022 | |
| Shire North American Group INC | $17.93 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.97 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $15.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Delgadillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.